Introduction
The cardiac I-123 MIBG (metaiodobenzylguanidine) scan is a nuclear medicine imaging test that assesses sympathetic cardiac innervation. MIBG is a norepinephrine analog that is taken up by sympathetic nerve endings via the norepinephrine transporter. In neurodegenerative diseases, loss of sympathetic innervation produces characteristic patterns that help differentiate between tauopathies and synucleinopathies[@goldstein2000].
Mechanism
How MIBG Works
Radioactive Tracer: I-123 labeled MIBG is injected intravenously
Uptake: MIBG is taken up by sympathetic nerve terminals through the norepinephrine transporter (NET)
Imaging: Single-photon emission computed tomography (SPECT) images the distribution of MIBG in the heart
Quantification: Early and delayed images are compared to calculate the heart-to-mediastinum (H/M) ratioSympathetic Denervation in Neurodegeneration
- Synucleinopathies (PD, DLB, MSA): Loss of postganglionic sympathetic neurons → reduced MIBG uptake
- Tauopathies (PSP, CBS, AD): Relative preservation of cardiac sympathetic innervation → normal or near-normal uptake
Clinical Utility
Differentiating Tauopathies from Synucleinopathies
| Pattern | Disease | H/M Ratio | Interpretation |
|---------|---------|-----------|----------------|
| Reduced | Parkinson's disease | <1.6 | Sympathetic denervation — synucleinopathy |
| Reduced | Dementia with Lewy bodies | <1.6 | Sympathetic denervation — synucleinopathy |
| Reduced | Multiple system atrophy | <1.6 | Sympathetic denervation — synucleinopathy |
| Normal | Corticobasal syndrome | >1.8 | Intact sympathetic — tauopathy |
| Normal | Progressive supranuclear palsy | >1.8 | Intact sympathetic — tauopathy |
| Normal | Alzheimer's disease | >1.8 | Intact sympathetic |
Sensitivity and Specificity
- Sensitivity for synucleinopathy: 80-90%
- Specificity for synucleinopathy: 85-95%
- Positive predictive value: High when combined with clinical assessment
- Negative predictive value: High for ruling out synucleinopathy in CBS/PSP
Interpretation
Early vs Delayed Imaging
| Parameter | Normal | Abnormal |
|-----------|--------|----------|
| Early H/M ratio | >1.8 | <1.6 |
| Delayed H/M ratio | >1.8 | <1.6 |
| Washout rate | <10%/hr | May be elevated |
Clinical Interpretation
- Preserved uptake (H/M >1.8): Suggests tauopathy (CBS, PSP) rather than synucleinopathy
- Reduced uptake (H/M <1.6): Suggests synucleinopathy (PD, DLB, MSA)
- Borderline (1.6-1.8): Correlate with clinical presentation; consider other tests
For This Patient
Given this patient's:
- Negative alpha-synuclein seed amplification assay
- Clinical presentation suspicious for CBS or PSP
- DAT scan confirmed dopamine neuron loss
Cardiac MIBG scan would be expected to show:
- Normal/near-normal uptake if CBS/PSP (tauopathy)
- Reduced uptake if there is an synucleinopathy component
This test can help determine if there is mixed pathology (tau + synuclein) if uptake is borderline.
Practical Considerations
Cost and Access
| Component | Cost (USD) |
|-----------|------------|
| Procedure | $1,500-2,500 |
| Insurance | Often requires pre-authorization |
| Availability | University hospitals with nuclear medicine |
Contraindications
- Absolute: Pregnancy, breastfeeding
- Relative: Recent beta-blocker use (interferes with uptake), clonidine
Test Procedure
Preparation: Fast for 4-6 hours; hold beta-blockers for 24 hours if possible
Injection: I-123 MIBG injected intravenously
Early imaging: 15-30 minutes post-injection
Delayed imaging: 3-4 hours post-injection
Total time: 4-5 hoursComparison to Other Autonomic Tests
Complementary Diagnostic Approaches
Cardiac MIBG scintigraphy provides unique information about post-ganglionic sympathetic neurons that complements other autonomic assessments. Each test evaluates different components of the autonomic nervous system[@treister2023].
| Test | Target | What It Measures | MIBG Advantage |
|------|--------|------------------|----------------|
| Cardiac MIBG | Post-ganglionic sympathetic | Cardiac sympathetic innervation | Direct visualization of sympathetic nerve terminals |
| HRV Analysis | Parasympathetic + sympathetic | Heart rate variability | Non-invasive, no radiation |
| Orthostatic Hypotension | Central autonomic | BP response to standing | Identifies neurogenic OH severity |
| QSART/TST | Post-ganglionic sudomotor | Sweat response | Evaluates peripheral autonomic fibers |
| Urodynamic Studies | Pelvic autonomic | Bladder function | Direct assessment of detrusor function |
When to Choose MIBG
MIBG is particularly valuable when:
Differential diagnosis is unclear between tauopathies (CBS, PSP) and synucleinopathies (PD, MSA, DLB)
Autonomic symptoms are ambiguous — MIBG provides objective sympathetic denervation evidence
Patient cannot tolerate invasive testing — MIBG is well-tolerated
Need to assess disease severity — MIBG uptake correlates with sympathetic neuron lossConsider other tests when:
- Patient has contraindications to nuclear imaging (pregnancy)
- Need comprehensive autonomic evaluation (use full battery)
- Resource-limited settings (HRV and OH testing are more accessible)
Diagnostic Algorithm Integration
Mermaid diagram (expand to render)
Centers Offering MIBG Scanning
United States
| Center | Location | Notes |
|--------|----------|-------|
| Mayo Clinic | Rochester, MN; Phoenix, AZ; Jacksonville, FL | Leading center for movement disorders, offers MIBG |
| Massachusetts General Hospital | Boston, MA | Autonomic disorders program |
| University of Pennsylvania | Philadelphia, PA | Parkinson's disease center |
| Cleveland Clinic | Cleveland, OH | Movement disorders program |
| UCLA Medical Center | Los Angeles, CA | Lewy body dementia program |
| Mount Sinai | New York, NY | Autonomic testing available |
| Johns Hopkins | Baltimore, MD | Movement disorders center |
International
| Center | Location | Notes |
|--------|----------|-------|
| Royal Free Hospital | London, UK | Autonomic unit |
| University College London | London, UK | PSP Research Centre |
| Karolinska Institutet | Stockholm, Sweden | Movement disorders |
| Tokyo Metropolitan Institute | Tokyo, Japan | High-volume center |
| Università di Bologna | Italy | Autonomic research |
| University of Tübingen | Germany | Movement disorders |
Finding a Center
Movement disorder specialists — Ask neurologist for referral
Nuclear medicine departments — University hospitals typically offer MIBG
Autonomic disorder centers — Often have MIBG as part of evaluation
Clinical trials — Search [ClinicalTrials.gov](https://clinicaltrials.gov) for "MIBG Parkinson" trialsReferences
[Goldstein DS, et al, Cardiac sympathetic denervation in Parkinson disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10979882/)
[Orimo S, et al, 123I-MIBG cardiac scintigraphy in Lewy body disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18796596/)
[Treister R, et al, Autonomic function testing in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/38041967/)Pathway Diagram
The following diagram shows the key molecular relationships involving Cardiac MIBG Scan for Parkinsonism discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)